An experimental blood test for pancreatic cancer is being evaluated by a commercial laboratory, an important milestone toward making the test available for patients.
VIVUS will be discussing its significant 2024 momentum during the J.P. Morgan Healthcare Conference, with an emphasis on what we as a company aim to achieve during the coming months around our novel ...